Massimo Pandolfo is Professor of Neurology and Director of the Laboratory of Experimental Neurology at the Université Libre de Bruxelles (ULB) in Brussels, Belgium. He is also Chief of Neurology at the ULB-Erasme University Hospital in Brussels. He is Fellow of the American Academy of Neurology (AAN), member of the AAN Science Committee, and co-chair of the European Academy of Neurology Scientific Panel on Translational Neurology.
He has published more than 200 peer-reviewed articles in the field of neurogenetics and of clinical and translational neuroscience.
Dr. Pandolfo has led the team that identified the Friedreich ataxia (FRDA) gene in 1996 and has since been at the forefront of basic, translational and clinical research on FRDA. He is the coordinator of European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS), a board member of the European Ataxia Study Group (ASG) and a member of National Ataxia Foundation (USA) scientific advisory board.
In addition to his seminal work on FRDA, Dr. Pandolfo has contributed to the clinical and genetic study of other inherited ataxias, of the genetics and pharmacogenetics of epilepsy, of several rare inherited neurological diseases, and of the genetic predisposition to stroke. He has been involved in multi-investigator translational programs and is a principal investigator on several clinical trials. Dr. Pandolfo current research focuses on dissecting the pathogenesis of inherited ataxias and epilepsies and on the development of small molecule and gene therapy-based approaches for the treatment of FRDA and other neurodegenerative diseases.
Dr. Pandolfo obtained his medical degree from the University of Milan, Italy, where he also completed his residency in Neurology. He has been Assistant Professor of Neurology at the National Neurological Institute C. Besta in Milan and at Baylor College of Medicine in Houston, TX, then Associate Professor at the Université de Montréal and Adjunct Professor at McGill University.